The Stuttering market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stuttering pipeline products will significantly revolutionize the Stuttering market dynamics.
DelveInsight’s “Stuttering Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Stuttering market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Stuttering market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Stuttering Market Forecast
Some of the key facts of the Stuttering Market Report:
The Stuttering market size was valued approximately ~USD 40 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2024, Noema Pharma’s NOE-105 experienced an increase in its Phase Transition Success Rate (PTSR) following the completion of a Phase IIb trial. The drug candidate’s PTSR for treating stuttering or stammering rose by nine points, reaching 56%. PTSR represents the likelihood, expressed as a percentage, of a drug successfully advancing from one development phase to the next.
In 2023, the EU4 countries and the UK collectively generated approximately USD 3.9 million, with expectations of significant compound annual growth. Within Europe, Germany and France held the largest market shares, followed by the UK and Italy, while Spain had the smallest market share for that year.
DelveInsight estimates that there were approximately 4,013,792 total prevalent cases of stuttering in the 7MM, with around 885,952 diagnosed prevalent cases in 2023. These numbers are expected to rise by 2034 due to better understanding of the condition and heightened awareness among healthcare professionals and the general public.
The total diagnosed prevalent cases of stuttering in the US were approximately 415,969,023. This number is expected to rise by 2034.
In 2023, the US accounted for about 47% of the total diagnosed prevalent cases of stuttering among the 7MM, with the EU4 and the UK making up nearly 38%, and Japan around 15%. These cases are expected to rise by 2034 due to improved diagnostic methods, resulting in more accurate identification and reporting globally.
According to DelveInsight’s analysis, in 2023, there was a gender-specific distribution of the disease showing male predominance, with approximately 664,464 cases, compared to around 221,488 cases in females among the total diagnosed prevalent cases in the 7MM. These numbers are expected to rise during the forecast period due to societal and cultural influences on reporting and diagnosis, possibly because males face less stigma or societal pressure to hide their speech difficulties compared to females.
Key Stuttering Companies: Emalex Biosciences, and others
Key Stuttering Therapies: Ecopipam (EBS-101), and others
The Stuttering epidemiology based on gender analyzed that males have higher prevalence rate than females with a ratio of 3:1
Stuttering Overview
Stuttering, also known as stammering, is a speech disorder characterized by disruptions in the flow of speech. These disruptions can include repetitions of sounds, syllables, or words, prolongations of sounds, and involuntary pauses or blocks where the person is unable to produce sounds. Stuttering can affect communication and may lead to social and emotional challenges.
Get a Free sample for the Stuttering Market Report:
https://www.delveinsight.com/report-store/stuttering-market
Stuttering Market
The dynamics of the Stuttering market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
“In conditions such as Stuttering, close collaboration among all stakeholders is important because collaborative studies and systematic data collection will help further in the understanding of disease pathophysiology. As a next step, a global prospective study will help all the research fraternity in better understanding of biomarkers and diagnostic tests which will be relevant for future therapeutic clinical trials.”
Stuttering Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Stuttering Epidemiology Segmentation:
The Stuttering market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Stuttering
Prevalent Cases of Stuttering by severity
Gender-specific Prevalence of Stuttering
Diagnosed Cases of Episodic and Chronic Stuttering
Download the report to understand which factors are driving Stuttering epidemiology trends @ Stuttering Epidemiological Insights
Stuttering Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stuttering market or expected to get launched during the study period. The analysis covers Stuttering market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Stuttering Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Stuttering treatment, visit @ Stuttering Medications
Stuttering Therapies and Key Companies
Ecopipam (EBS-101): Emalex Biosciences
Stuttering Market Drivers
Increasing prevalence
No approved drug (huge opportunity in the market)
Genetic findings
Increasing awareness in parents
Stuttering Market Barriers
Underdiagnoses
Treatment guidelines and recommendations are focused on non-pharmacologic therapy
Challenges in the management of the disease
Insufficient knowledge of the pathogenesis
Scope of the Stuttering Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Stuttering Therapeutic Assessment: Stuttering current marketed and Stuttering emerging therapies
Stuttering Market Dynamics: Stuttering market drivers and Stuttering market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Stuttering Unmet Needs, KOL’s views, Analyst’s views, Stuttering Market Access and Reimbursement
Discover more about therapies set to grab major Stuttering market share @ Stuttering Clinical Trials and Therapeutic Assessment
Table of Contents
1. Stuttering Market Report Introduction
2. Executive Summary for Stuttering
3. SWOT analysis of Stuttering
4. Stuttering Patient Share (%) Overview at a Glance
5. Stuttering Market Overview at a Glance
6. Stuttering Disease Background and Overview
7. Stuttering Epidemiology and Patient Population
8. Country-Specific Patient Population of Stuttering
9. Stuttering Current Treatment and Medical Practices
10. Stuttering Unmet Needs
11. Stuttering Emerging Therapies
12. Stuttering Market Outlook
13. Country-Wise Stuttering Market Analysis (2020–2034)
14. Stuttering Market Access and Reimbursement of Therapies
15. Stuttering Market Drivers
16. Stuttering Market Barriers
17. Stuttering Appendix
18. Stuttering Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/blog/
